Finance entity
Every one of those 1 sits in a single category, markets. Compass Pathways plc is most often covered alongside Genmab A/S, which appears in 1 of these 1 story. Compass Pathways plc appears in 1 tracked Finance story from February 17, 2026.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, markets. Compass Pathways plc is most often covered alongside Genmab A/S, which appears in 1 of these 1 story. Compass Pathways plc appears in 1 tracked Finance story from February 17, 2026. The tracked stories average 9 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Compass Pathways plc. Shared-story counts are live from our verified record — not editorial picks.
The equity markets are navigating a complex landscape of 'sell-the-news' reactions and extreme biotech volatility following a series of clinical and financial updates. While Compass Pathways surged on positive trial results, Ocular Therapeutix and Genmab faced significant selling pressure despite reaching key milestones.
Compass Pathways plc is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
